Product Description
Mechanisms of Action: EP1 Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | France | Germany | Italy | Malaysia | New Zealand | Singapore | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Abortion, Incomplete|Abortion, Spontaneous|Abortion, Missed
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FF-2021-504 | P2 |
Completed |
Abortion, Spontaneous|Abortion, Missed|Abortion, Incomplete |
2024-10-28 |
2025-06-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2024 |
PubMed |
Abortion medical management between 14-16 weeks' amenorrhea after French legislation deadline extension. |
|
10/03/2023 |
PubMed |
Exploring the Safety and Efficacy of Medical Termination of Pregnancy: A Comprehensive Review. |
|
09/29/2023 |
PubMed |
Triple repeated fetal congenital heart disease linked to PLD1 mutation: a case report. |